A possible pharmacological explanation for quinacrine failure to treat prion diseases: Pharmacokinetic investigations in a ovine model of scrapie

British Journal of Pharmacology

Volumn 144, Issue 3, 2005, Pages 386-393

  Gayrard, Véronique ^a   Picard Hagen, Nicole ^a   Viguié, Catherine ^a   Laroute, Valerie ^a   Andréoletti, Olivier ^a   Toutain, Pierre Louis ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Creutzfeldt Jakob disease (CJD); Neuroblastoma; Pharmacokinetics; Prion; Quinacrine; Scrapie; Therapeutic

Indexed keywords

MEPACRINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; EXTRACELLULAR SPACE; IN VITRO STUDY; INTRACELLULAR SPACE; MOUSE; NEUROBLASTOMA; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; SCRAPIE;

ALGORITHMS; ANIMALS; CELL LINE, TUMOR; CULTURE MEDIA; EXTRACELLULAR SPACE; FEMALE; INJECTIONS, INTRAMUSCULAR; PRION DISEASES; QUINACRINE; SCRAPIE; SHEEP; SHEEP DISEASES; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 14644389457     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706072     Document Type: Article

References (22)

1. BARRET, A., TAGLIAVINI, F., FORLONI, G., BATE, C., SALMONA, M., COLOMBO, L., DE LUIGI, A., LIMIDO, L., SUARDI, L., ROSSI, G., AUVRÉ, F., ADJOU, K.T., SALÈS, N., WILLIAMS, A., LASMÉZAS, C. & DESLYS, J.P. (2003). Evaluation of quinacrine treatment for prion diseases. J. Virol., 77, 8462-8469.
2. BJÖRKMAN, S. & ELISSON, L.O. (1987). Determination of quinacrine (mepacrine) in plasma by high-performance liquid chromatography with fluorimetric detection. J. Chromatogr., 420, 341-348.
3. BRUCE, M.E., MCBRIDE, P.A. & FARQUHAR, C.F. (1989). Precise targeting of the pathology of the sialoglycoprotein, PrP, and vacuolar degeneration in mouse scrapie. Neurosci. Lett., 102, 1-6.
4. COLLINS, S.J., LEWIS, V., BRAZIER. M., HILL, A.F., FLETCHER, A. & MASTERS, C.L. (2002). Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann. Neurol., 52, 503-506.
5. DE LANGE, E.C.M. & DANHOF, M. (2002). Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin. Pharmacokinet., 41, 691-703.
6. DOHGU, S., YAMAUCHI, A., TAKATA, F., SAWADA, Y., HIGUCHI, S., NAITO, M., TSURUO, T., SHIRABE, S., NIWA, M., KATAMINE, S. & KATAOKA, Y. (2004). Uptake and efflux of quinacrine, a candidate for the treatment of prion diseases, at the blood-brain barrier. Cell. Mol. Neurobiol., 24, 205-217.
7. DOH-URA, K., IWAKI, T. & CAUGHEY, B. (2000). Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J. Virol., 74, 4894-4897.
8. DUBIN, N.H., BLAKE, D.A., DIBLASI, M.C., PARMLEY, T.H. & KING, T.M. (1982). Pharmacokinetic studies on quinacrine following intrauterine administration to cynomolgus monkeys. Fertil. Steril., 38, 735-740.
9. FOLLETTE, P. (2003). New perspectives for prion therapeutics meeting. Prion disease treatment's early promise unravels. Science, 299, 191-192.
10. FURUKAWA, H., TAKAHASHI, M., NAKAJIMA, M. & YAMADA, T. (2002). Prospects of the therapeutic approaches to Creutzfeldt-Jakob disease: a clinical trial of antimalarial, quinacrine. Nippon Rinsho, 60, 1649-1657.
11. GIBALDI, M. & PERRIER, D. (1982). Pharmacokinetics, 2nd edn. New York: Marcel Dekker Inc.
12. GOODMAN, L.S. & GILMAN, A. (1960). Quinacrine. In: The Pharmacological Basis of Therapeutics, 2nd edn, ed. Goodman, L.S. & Gilman, A. pp. 1167-1173. New York: Macmillan.
13. JENDROSKA, K., HEINZEL, P.P., TORCHIA, M., STOWRING, L., KRETZSCHMAR, H.A., KON, A., STERN, A., PRUSINER, S.B. & DEARMOND, S.J. (1991). Proteinase-resistant prion protein accumulation in Syrian hamster brain correlates with regional pathology and scrapie infectivity. Neurology, 41, 1482-1490.
14. KORTH, C., MAY, B.C.H., COHEN, F.E. & PRUSINER, S.B. (2001). Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. U.S.A., 98, 9836-9841.
15. LEHMANN, S. & HARRIS, D. (1995). A mutant prion protein displays an aberrant membrane association when expressed in cultured cells. J. Biol. Chem., 270, 24589-24597.
16. NAKAJIMA, M., YAMADA, T., KUSUHARA, T., FURUKAWA, H., TAKAHASHI, M., YAMAUCHI, A. & KATAOKA, Y. (2004). Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement. Geriatr. Cogn. Disord., 17, 158-163.
17. O'NEILL, P.M., BRAY, P.G., HAWLEY, S.R., WARD, S.A. & PARK, B.K. (1998). 4-Aminoquinolines - past, present, and future: a chemical perspective. Pharmacol. Ther., 77, 29-58.
18. SCHELCHER, F., PICARD-HAGEN, N., LAROUTE, V., GAYRARD, V., POPOT, M.A., ANDRÉOLETTI, O. & TOUTAIN, P.L. (1999). Corticoid concentrations are increased in the plasma and urine of ewes with naturally occurring scrapie. Endocrinology, 140, 2422-2425.
19. SHANNON, J.A., EARLE, D.P., BRODIE, B.B., TAGGART, J.V. & BERLINER, R.W. (1944). The pharmacological basis for the rational use of atabrine in the treatment of malaria. J. Pharmacol. Exp. Ther., 81, 307-330.
20. SHYNG, S.L., HUBER, M.T. & HARRIS, D.A. (1993). A prion protein cycles between the cell surface and an endocytic compartment in cultured neuroblastoma cells. J. Biol. Chem., 268, 15922-15928.
21. VOGTHERR, M., GRIMME, S., ELSHORST, B., JACOBS, D.M., FIEBIG, K., GRIESINGER, C. & ZAHN, R. (2003). Antimalarial drug quinacrine binds to the C-terminal helix of cellular prion protein. J. Med. Chem., 46, 3563-3564.
22. YAMAOKA, K., NAKAGAWA, T. & UNO, T. (1978). Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm., 6, 165-175.